Petros Pharmaceuticals, Inc. (PTPI) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 New York City, NY, 미국. 현재 CEO는 Fady Boctor.
PTPI 을(를) 보유 IPO 날짜 2020-12-02, 18 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $180.73K.
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
